Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
Market Analysis and Insights: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market
The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at US$ 8816.2 in 2020 and will reach US$ 18650 million by the end of 2027, growing at a CAGR of 13.3% during 2022-2027.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Scope and Market Size
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glucagon Like Peptide-1 (GLP-1) Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
The Glucagon Like Peptide-1 (GLP-1) Agonists market is analysed and market size information is provided by regions (countries). Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
Market Analysis and Insights: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market
The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at US$ 8816.2 in 2020 and will reach US$ 18650 million by the end of 2027, growing at a CAGR of 13.3% during 2022-2027.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Scope and Market Size
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glucagon Like Peptide-1 (GLP-1) Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
The Glucagon Like Peptide-1 (GLP-1) Agonists market is analysed and market size information is provided by regions (countries). Segment by Application, the Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
